Pioglitazone for Idiopathic Gastroparesis

Early Phase 1CompletedNCT04300127

Johns Hopkins University14 enrolled

Overview

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

Objective • The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index Daily Diary (GCSI-DD) in patients with Idiopathic Gastroparesis Secondary objectives of this study include: * To determine the effects of pioglitazone on other symptoms associated with gastroparesis using the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) and the Gastrointestinal Symptom Rating Scale (GSRS), * To determine the effects of pioglitazone on gastric emptying as measured by the 13C- Spirulina breath test, * To determine the effects of pioglitazone on satiety as measured by a liquid caloric test * To determine the effects of pioglitazone on depression and anxiety using the Beck Depression Inventory and State-Trait Anxiety Scores, * To determine the effects of pioglitazone on Quality of Life using the PAGI-QoL and Short Form (SF)-36 questionnaire, * To determine the effects of pioglitazone on markers of inflammation (CRP and ESR) and serum cytokine levels * To determine the nature and incidence of adverse effects from a 12-week course of pioglitazone. Treatment group • Pioglitazone (30 mg po qd) Population • Age 18 years or older at registration with nausea, vomiting, and other symptoms suggestive of patients with chronic nausea and vomiting of presumed gastric origin, with symptomatic gastroparesis. Study duration * Up to 4 weeks of screening prior to pioglitazone treatment * 8 weeks of treatment starting at initial dose of pioglitazone * 4 weeks of washout period * Length of recruitment: 16 months Sample size justification * Total of 23 patients * Primary comparison: Baseline PAGI-SYM score versus 4, 8, and 12 weeks. Number of clinical centers • Johns Hopkins Bayview Medical Center.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastroparesis

Interventions

Pioglitazone 30 mgDRUG

Patients will received 30 mg of Pioglitazone once a day for 8 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older at registration * Diagnosis of gastroparesis as documented by gastric emptying scintigraphy (4-hour emptying after a low-fat meal with any combination of 2 and 4 hour retention of \>60% and 10% respectively) * Ongoing symptoms referable to gastroparesis (i.e. Nausea and vomiting, bloating, and abdominal pain) * Exclusion of other causes of symptoms such as mechanical gastrointestinal obstruction, uncontrolled esophagitis, peptic ulcer disease, etc. By standard radiographic or endoscopic tests * Females will be required to use adequate contraceptive methods during study participation as determined by the Principal Investigator and the study team members Exclusion Criteria: * Another active disorder, which could explain symptoms in the opinion of the investigator * Age \< than 18 years * Pregnancy or nursing * Previous surgery of the upper gastrointestinal tract, including vagotomy * Another active disorder, which could explain symptoms in the opinion of the investigator * Use of narcotics more than 3 days per week * Significant hepatic injury as defined by significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations of greater than 2 x upper limit of normal (ULN) or a Child-Pugh score of 10 or greater * Serious systemic disease, such as recent myocardial infarction/unstable angina, decompensated congestive heart failure, severe pulmonary disease with dyspnea at rest, or altered mental status from any cause * Diabetes as defined by HbA1c \>6.5 and/or fasting blood sugar of \>125 mg/DL * Contraindications to pioglitazone such as hypersensitivity or allergy * Concurrent use of: estradiol, ethynyl estradiol, mestranol, pazopanib, warfarin, digoxin, atorvastatin, ranitidine, gemfibrozil, fexofenadine, midazolam * Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study * History of bladder cancer or family history of bladder cancer * Failure to give informed consent

Locations (1)

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index

The effect of Pioglitazone on nausea, early satiety, postprandial fullness, and upper abdominal pain as per changes in patient scoring in The American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index (GCSI) which has been designed to assess symptoms associated with gastroparesis. Symptoms are rated as none (0), mild (1), moderate (2), severe (3), very severe (4) scale of the worst severity of the symptom over the last 24 hours. Values reported represent the mean participant scale choice.

Time frame: Baseline, later monthly up to 3 months.

Secondary Outcomes

Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM)

The Patient Assessment of Gastrointestinal Symptoms (PAGI-SYM) questionnaire is a patient-reported tool designed to evaluate the severity of upper gastrointestinal symptoms across multiple domains, including nausea/vomiting, postprandial fullness/early satiety, bloating, upper abdominal pain, and heartburn/regurgitation. Each symptom is rated on a 0 to 5 Likert scale, where 0 indicates no symptoms and 5 represents very severe symptoms, with higher scores reflecting worse symptom severity. The total PAGI-SYM score is typically calculated as the average of individual domain scores, resulting in a possible score range of 0 to 5. The mean participant scale choice is reported.

Time frame: Baseline and later monthly up to 3 months

Functional Status as Assessed by the SF-36v2 Health Survey

The effect of Pioglitazone on quality of life assessed by the SF-36v2 Health Survey. The SF-36v2 is a 36-item, self-report measure designed to assess quality of life in patients. This measure also provides two summary scores (physical and mental health) and eight scale scores. The eight sections are: vitality, physical functioning, bodily pain and general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability, i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.